-Enrollment expected to begin in early 2022 - TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announ
Flora’s cultivation and extraction division, Cosechemos, completed construction of a 10,500 ft2 state-of-the-art post-harvest and extraction facility with annual capacity of 15,000 L of distillate The first batch of crude oil has been extracted, wh
$30.4 million net revenue represents a record for the Company as it solidifies #4 market share position nationally among Canadian LPs HIGHLIGHTS 23% growth in gross revenue to $44.3 million from Q4 Fiscal 2021 and 75% from the same prior-year period
Health Canada rules that 40 mg/0.4 mL and 80 mg/0.8 mL presentations of SIMLANDI™ are not subject to the statutory stay, clearing the way for the launch in the Canadian market High-concentration formulations, previously unavailable in Canada, reflect
Phase 1b/2a trial of NervGen’s lead compound, NVG-291, is based upon unprecedented, peer-reviewed animal studies demonstrating pronounced functional recovery from spinal cord injury “The ability of NVG-291 to demonstrate meaningful recovery in mo
Expands Pfizer’s access to lipid nanoparticle (LNP) formulation technology, offering a strong strategic fit with Pfizer’s mRNA strategy Pfizer gains option to license Acuitas’ LNP technology for up to 10 targets for vaccine or therapeutic developm
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and dev
Majority Support from Noteholders Already Confirmed Enables Company to Fund Continued Growth, Enhance Scale and Drive Profitability NEW YORK--(BUSINESS WIRE)--Columbia Care Inc. (NEO: CCHW) (CSE:CCHW) (OTCQX:CCHWF) (FSE: 3LP) (“Columbia Care” or the
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on psychedelic pharmaceutical therapies, is pleased to announce that Adelia Therapeutics Inc. (“Adelia”), a wholly
TORONTO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Deep Genomics, the leading AI RNA therapeutics company, today announced that its Founder and CEO, Brendan Frey, PhD, FRSC, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.